Clarity Pharmaceuticals Company Description

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults.

Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.

The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen.

The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer.

Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Clarity Pharmaceuticals Ltd

Country	Australia
Founded	2010
Industry	Biotechnology
Sector	Healthcare
Employees	88
CEO	Michelle Parker

Contact Details

Address: National Innovation Centre Sydney, NSW NSW Australia
Phone	61 2 9209 4037

Stock Details

Ticker Symbol	CU6
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000165375
SIC Code	2834

Key Executives

Name	Position
Michelle Parker	Chief Executive Officer, MD and Executive Director
Dr. Alan John Taylor Ph.D.	Executive Chairman
David K. Green BEc., CA	Chief Financial Officer
Dr. Colin David Biggin Ph.D.	Chief Operating Officer
Dr. Ellen van Dam Ph.D.	Chief Scientific Officer
Lisa Sadetskaya	Director of Corporate Communications.
Mary Bennett	Head of People and Culture
Shaemus Gleason	Executive Vice President of Operations
Dr. Othon Gervasio	Chief Medical Officer
Eva Lengyelova	Executive Vice President of Clinical Development